🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company87 Merck Sharp & Dohme LLC70 Janssen Research & Development, LLC67 AbbVie66
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Georgia

2350 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Gemcitabine·Carboplatin
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho
2025-03-16
Active, closed
Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
NCT06495424Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Averitas Pharma, Inc.
Observational
144
Delaware, Georgia, Kentucky, New Jersey, Ohio, Pennsylvania
2025-03-14
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Active, closed
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Paclitaxel
Celgene
Phase 3
960
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-03-13
Recruiting
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
NCT06915246Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
VIVUS LLC
Phase 2
49
Arizona, California, Georgia, Illinois
2025-03-12
Active, closed
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
3,853
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho
2025-03-12
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsBMS-986393·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Alabama, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2025-03-12
Recruiting
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
NCT06788756Acute Myeloid Leukaemia (AML)
DrugCytarabine
Moleculin Biotech, Inc.
Phase 2/3
312
Alabama, Florida, Georgia, Nebraska, New Jersey, Ohio, Pennsylvania, Rhode Island
2025-03-12
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Active, closed
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 3
480
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-03-11
Active, closed
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
DrugAR882
Arthrosi Therapeutics
Phase 3
750
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2025-03-11
Active, closed
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802Encephalitis
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-03-10
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey
2025-03-07
Active, closed
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026Psoriatic Arthritis, Overweight or Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
Active, closed
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.
Not applicable
55
California, Florida, Georgia, Missouri, Tennessee, Texas, Wisconsin
2025-03-06
Active, closed
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268Obesity
DrugRetatrutide
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Active, closed
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
NCT06824987APOL1-Mediated Kidney Disease
AstraZeneca
Phase 2
57
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-05
Active, closed
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988Macular Neovascularization Secondary to Age-Related Macular Degeneration
DrugsEYLEA (aflibercept)·4D-150 IVT
4D Molecular Therapeutics
Phase 3
480
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-03-03
Active, closed
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
NCT06874621Alzheimer's Disease (AD)
Voyager Therapeutics
Phase 1/2
52
California, Connecticut, Florida, Georgia, New Jersey, North Carolina, Pennsylvania
2025-03-03
Recruiting
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044Major Depressive Disorder (MDD)
Vanda Pharmaceuticals
Phase 3
500
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-03-03
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-03-03
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-03
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Oxaliplatin
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Active, closed
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
NCT06838000Pneumococcal Infections
Drugs20vPCV·Capvaxive
Sanofi Pasteur, a Sanofi Company
Phase 3
1,268
California, Florida, Georgia, Iowa, Kentucky, Mississippi, Nebraska, New York
2025-02-28
Active, closed
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
NCT06856577Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
DrugAflibercept
Adverum Biotechnologies, Inc.
Phase 3
311
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-02-28
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
600
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana
2025-02-28
Active, closed
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
NCT06812988Type 1 Diabetes Mellitus
DrugBrivekimig
Sanofi
Phase 2
84
Georgia, Michigan, Texas, Utah
2025-02-28
Recruiting
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212Schizophrenia
DrugSEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
522
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland, New Jersey
2025-02-28
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsPembrolizumab·Bevacizumab
Summit Therapeutics
Phase 3
780
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
171
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
NCT06884865Osteoarthritis (OA) of the Knee
Pacira Pharmaceuticals, Inc
Phase 2
135
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-02-26
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsAtezolizumab·Etoposide·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Alabama, Arkansas, Florida, Georgia, Illinois, Minnesota, New Mexico, North Carolina
2025-02-25
Recruiting
Prevail Global Study
NCT06535854Coronary Artery Disease
Medtronic Vascular
Not applicable
1,205
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-02-24
Recruiting
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
20
Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas
2025-02-21
By invitation
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder
NCT06878976Binge-Eating Disorder
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
236
California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey
2025-02-20
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
56
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts
2025-02-19
Active, closed
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194Pneumococcal Immunization
Sanofi
Phase 3
2,360
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-02-18
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Lighthouse Pharmaceuticals, Inc.
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana, Maryland
2025-02-17
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
NCT06778447Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
VIVEX Biologics, Inc.
Not applicable
325
California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana
2025-02-17
Recruiting
OurRelationship-S: A Digital Relationship-Strengthening Program for Couples Experiencing Substance Misuse
NCT07159633Relationship Conflict, Relationship Distress
OurRelationship
Not applicable
120
Georgia, Maryland, New York, South Carolina, Texas
2025-02-15
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
Recruiting
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
NCT06822738Primary Open Angle Glaucoma
AbbVie
Phase 3
130
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2025-02-11
Recruiting
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
NCT06616025Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
Neuraptive Therapeutics Inc.
Phase 3
98
California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-02-10
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2025-02-06
Recruiting
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629Proteinuric Kidney Disease
Maze Therapeutics
Phase 2
74
Alabama, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2025-02-05
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-02-05
Active, closed
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014Early Alzheimers Disease
DrugBuntanetap/posiphen
Annovis Bio Inc.
Phase 3
760
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-02-04
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-02-03
Recruiting
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489Major Depressive Disorder
DrugZelquistinel
Syndeio Biosciences, Inc
Phase 2
164
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2025-02-03
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Atezolizumab·Etoposide·Carboplatin
BioNTech SE
Phase 3
621
Arizona, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana
2025-02-03
Recruiting
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527Rotator Cuff Tears of the Shoulder
Anika Therapeutics, Inc.
Not applicable
150
Arizona, California, Florida, Georgia, Indiana, Maryland, New Jersey, South Carolina
2025-02-01
Active, closed
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06769048Geographic Atrophy
Boehringer Ingelheim
Phase 2
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-31
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugsRemibrutinib A·Remibrutinib B
Novartis Pharmaceuticals
Phase 3
588
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-01-31
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06514794T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Active, closed
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595Generalized Anxiety Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
245
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New Jersey, Ohio
2025-01-29
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Prednisolone·Methylprednisolone
Merck Sharp & Dohme LLC
Phase 3
1,046
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-01-27
By invitation
A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
NCT06701201Cancer
DrugSynKIR-310
Verismo Therapeutics
Observational
60
Colorado, Georgia, Kansas, New Jersey, Pennsylvania, Texas, Wisconsin
2025-01-27
Recruiting
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugALKS 2680
Alkermes, Inc.
Phase 2/3
256
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-01-27
Recruiting
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
180
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-01-24
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
United Therapeutics
Observational
900
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-23
Active, closed
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773Geographic Atrophy, Macular Degeneration
DrugAvacincaptad Pegol
Astellas Pharma Global Development, Inc.
Observational
489
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2025-01-22
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
240
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-21
Recruiting
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06568939Non-Small Cell Lung Cancer
DrugTelisotuzumab vedotin
AbbVie
Phase 2
150
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-01-20
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-01-17
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-15
Recruiting
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543Colorectal Cancer
DrugFruquintinib
Takeda
Phase 4
78
Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Indiana
2025-01-14
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
DrugsIMA203·Lifileucel·Relatlimab·Dacarbazine
Immatics US, Inc.
Phase 3
360
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2025-01-14
Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
NCT06011551Degenerative Disc Disease (DDD)
ReGelTec, Inc.
Not applicable
225
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kansas, Louisiana
2025-01-13
Recruiting
Post-Market Clinical Investigation Plan- Collagen Dural Regeneration Matrix (DuraMatrix-Onlay Plus)
NCT06802133Repair of Dura Mater
Collagen Matrix
Observational
118
Georgia, Massachusetts
2025-01-13
Active, closed
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016Female Contraception
Mylan Pharmaceuticals Inc
Phase 3
1,630
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky
2025-01-13
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
NCT06516653End Stage Renal Disease
Laminate Medical Technologies
Not applicable
300
California, Florida, Georgia, Massachusetts, Mississippi, Nevada, South Carolina, Texas
2025-01-13
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122Type 2 Diabetes
DrugDulaglutide
Eli Lilly and Company
Phase 3
55
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-01-10
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06740630Chickenpox
DrugMMR vaccine
GlaxoSmithKline
Phase 3
1,840
Alabama, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-10
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462Rheumatoid Arthritis
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
120
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-01-10
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-01-10
Recruiting
Pan-tumor MRD Study
NCT06605404Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer)
Paradigm Health
Observational
1,350
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-01-08
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
DrugsPumitamig·Pemetrexed·Carboplatin·Pembrolizumab
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
DrugRaludotatug Deruxtecan
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsPF-07220060·Ribociclib·Abemaciclib·Palbociclib
Pfizer
Phase 3
1,035
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-01-06
Active, closed
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06722157Macular Degeneration, Age-related, Geographic Atrophy
DrugPegcetacoplan
Boehringer Ingelheim
Phase 2
202
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-06
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugPirtobrutinib
Loxo Oncology, Inc.
Phase 2
249
Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky, Maryland
2025-01-03
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830Treatment Resistant Depression
atai Therapeutics, Inc.
Phase 2
142
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland
2024-12-30
Active, closed
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
35
Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kentucky
2024-12-30
Recruiting
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457Staphylococcus Aureus
AstraZeneca
Phase 1/2
231
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2024-12-30
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
DrugPembrolizumab
Alnylam Pharmaceuticals
Phase 1
158
Arizona, California, Florida, Georgia, Illinois, Michigan, Minnesota, New York
2024-12-30
Recruiting
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06752668Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
248
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Michigan
2024-12-23
Active, closed
A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
NCT06688058Healthy
DrugGARDASIL9
Merck Sharp & Dohme LLC
Phase 1
72
Florida, Georgia, Missouri, Tennessee
2024-12-20
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379Major Depressive Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-12-20
Active, closed
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985Hepatocellular Carcinoma
DrugsBevacizumab·Tislelizumab
Coherus Oncology, Inc.
Phase 2
72
Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky, Mississippi
2024-12-20
Active, closed
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Observational
401
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2024-12-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
DrugsBrivekimig·Rilzabrutinib·Frexalimab
Sanofi
Phase 2
84
Alabama, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nevada
2024-12-19
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2024-12-19
Rows per page Showing 801–900 of 2350
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia?page=9

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,350 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,212 of the 2,350 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 40 have not yet opened recruitment, 1,038 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.